Medical Need is the new distribution partner for CIMAher® in the Nordics
Oncoscience | May 21st, 2018
Oncoscience GmbH announced today that it has entered into an exclusive supply and distribution agreement with Swedish based Medical Need AB regarding the distribution, marketing and sale of CIMAher® (Nimotuzumab) in the Nordics. Under the agreement, Medical Need AB gains the rights to distribute CIMAher® in Denmark, Finland, Iceland, Norway and Sweden, and will initially do so on a named patient basis in the territories.
Tomas Gloveus, the Head of Marketing and Sales at Medical Need AB said, “CIMAher® addresses a significant unmet medical need for many patients with severe cancers, who are currently left to treatment alternatives with severe side-effects and we look forward to making CIMAher® available in the Nordic countries.”
Dr. Dirk Reuter, the Managing Director of Oncoscience GmbH added, “The niche focus combined with their capabilities within oncology, makes Medical Need a very suitable partner for us in the Nordics, and we look forward to working together to improve the access of CIMAher® in the Nordic region.”
Nimotuzumab is a well-established monoclonal antibody within oncology that targets the epidermal growth factor receptor (EGFR) on cancer cells and inhibits their signalling pathway which stops cancer cells from growing and proliferating. To date, Nimotuzumab has been administered to more than 65,000 patients globally and has undergone 82 clinical studies. Nimotuzumab is already approved in 25 countries around the world for a variety of cancers, such as head & neck cancer, oesophageal cancer, highly malignant brain tumours and pancreatic cancer.
Nimotuzumab has an EU orphan designation for the treatment of pancreatic cancer and glioma and has been used in EU under named patient basis, following special individual approvals from a national regulatory authority as it does not yet hold a EU marketing authorization.
About CIMAher® (Nimotuzumab)
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Nimotuzumab’s capacity to bind to EGFR is strongly dependant on cell receptor density and it’s bivalent binding mechanism. EGRF is overexpressed in many cancer cells as compared to normal tissue and nimotuzumabs bivalent binding mechanism results in more specific bonds and therefore, potentially increases anti-tumor activity with decreased toxicity in normal tissue (i.e. skin and healthy organ toxicity).
Nimotuzumab is currently available as a registered treatment in 25 countries around the world for a variety of cancers, including head & neck cancers in advanced stages, nasopharyngeal carcinoma, oesophageal cancer, high-malignant glial cancers (glioblastoma multiforme and anaplastic astrocytoma), and locally advanced or metastatic pancreatic cancer (adenocarcinoma). Nimotuzumab has also been approved in a number of countries for high-grade gliomas in children and adolescents (newly diagnosed, recurrent and refractory).
About Medical Need AB
Medical Need Europe AB is a privately held, Sweden based pharmaceutical company, focusing on the development, registration, distribution, marketing and sale of orphan drugs and niche specialty pharmaceuticals, as well as provision of unlicensed medicines fulfilling unmet medical needs on a named patient basis in Europe.
Our mission is to be a full-service partner that offers a turnkey solution for commercialization of niche pharmaceuticals in Europe, regardless of size, and which identifies and satisfies unmet medical needs of individual patients and situations in health care. We offer existing infrastructure and networks across a broad range of therapeutic areas, with a very successful track record.
The company is currently active within several rare and niche conditions, such as; Urea Cycle Disorders, Niemann-Pick type C, errors of bile acid synthesis, Congenital-Sucrase-Isomaltase Deficiency, progressive multiple sclerosis (MS), haematological stem cell transplantation, multiple myeloma, multi-drug resistant tuberculosis and Menière’s disease.
For more information, please visit: www.medicalneed.com
About Oncoscience GmbH
Oncoscience is a German based, privately-owned clinical-stage biopharmaceutical company founded in 2001 to advance the clinical development of novel products for the treatment of orphan indications in oncology. Oncoscience has the exclusive rights for the anti-EGFR monoclonal antibody Nimotuzumab, in the European Union and the surrounding area (in total 46 countries). Oncoscience is committed to further developing Nimotuzumab in Europe to address oncological diseases for which the unmet medical need is high and for which effective and safe therapy is urgently needed